Polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel as well as preparation method and application thereof

By developing polyethylene glycol diacrylate/cysamine/agumamine medical hydrogel, the problem of neurologic function recovery after craniocerebral injury has been solved, and the ROS and NO levels have been reduced, and the scaffolds have been provided to support cell regeneration and regulate the degradation rate. Effect, suitable for the treatment of craniocerebral injury.

CN118903545APending Publication Date: 2024-11-08NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410973527.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing treatment methods cannot effectively improve the recovery of neurological function after severe craniocerebral injury, and the complex structure of brain tissue makes it difficult to treat. The existing hydrogels have shortcomings in functional recovery.

Method used

Develop a polyethylene glycol diacrylate/cysamine/agumamine medical hydrogel, which forms a highly crosslinked network polymer hydrogel through Michael addition reaction, which has good adhesion and philtrum Aqueous and biocompatible, capable of degrading and releasing agmatamine to promote nerve regeneration.

Benefits of technology

The hydrogel can significantly reduce the ROS level and NO concentration of the damaged site, provide scaffolds to support cell regeneration, enhance brain function recovery, and adapt to the repair needs of the damaged site by regulating the degradation rate and release rate, and is injectable and minimally invasive. Delivery capability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903545A_ABST
    Figure CN118903545A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of tissue engineering and biological materials, and discloses polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing polyethylene glycol diacrylate, cystamine and agmatine according to a certain molar ratio, dissolving the weighed polyethylene glycol diacrylate, cystamine and agmatine in ddH2O with a pH value of 8-8.5, and carrying out a Michael addition reaction under certain conditions to prepare the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel. The medical hydrogel can fill the vacancy of brain injury tissues, protect the injury part, inhibit the generation of NO in the brain injury tissues and promote the recovery of brain trauma. According to the invention, bioactive agmatine and reducing cystamine are combined into the hydrogel to repair traumatic brain injury, and a new treatment thought is provided for recovery of functions of a central nervous system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of tissue engineering and biomaterials, and in particular relates to a polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel and a preparation method and application thereof. Background Art

[0002] The physiological and pathological mechanisms of traumatic brain injury mainly include damage caused by primary external impact and neural, metabolic, cellular and other reactions caused by secondary damage. Post-traumatic inflammation can cause chronic neuroinflammation and related neurodegenerative lesions, especially in chronic neurodegenerative diseases, accompanied by worsening neurological dysfunction. At present, clinical treatment for severe craniocerebral injury usually requires craniotomy, and existing treatment methods cannot effectively improve the patient's neurological function recovery. Due to the complex pathological and physiological structure of brain tissue, cavities are formed at the site of brain injury, and the neuroinflammatory response causes the injury site to recruit macrophages and activated microglia, releasing additional nitric oxide (NO) and reactive oxygen species (ROS) that accumulate in the damaged brain tissue, creating a toxic microenvironment that is toxic to surrounding neurons and inhibits neuronal regeneration.

[0003] Hydrogels are networks composed of water molecules and hydrophilic polymers. Their high water content enables them to dissolve and transport ions and many small molecules. The resulting polymer network is typically sparsely cross-linked, making the hydrogel soft and elastic. Hydrogels share the characteristics of extracellular matrix: 1) high water content and good biocompatibility; 2) pure hydrogels can provide a 3D growth environment for cells and mechanical support, but lack the ability to repair damaged living tissue.

[0004] Due to the structural properties of hydrogels, they can be tuned through a variety of chemical methods. Through rational design, bioactive hydrogels can be prepared, loaded with hydrophilic drugs or bioactive molecules, thus promoting the functional recovery of damaged native tissues. Furthermore, the degradation properties of hydrogels are crucial. For short-term implants, biomaterials must be biodegradable, degrading in vivo as the wound heals, avoiding secondary surgical removal.

[0005] In summary, it is indeed necessary to provide a hydrogel that can promote the functional recovery of damaged natural tissues for use in the treatment of craniocerebral injuries. Summary of the Invention

[0006] In order to solve the above-mentioned existing technical problems or part of them, the purpose of the present invention is to provide a polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel and its preparation method and application. The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel is degradable and has the ability to promote the functional recovery of damaged natural tissues.

[0007] The following is adapted according to the modifications of the claims.

[0008] According to one aspect of the present invention, a polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel is provided, wherein the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel comprises:

[0009] Water molecules;

[0010] The polymer of polyethylene glycol diacrylate / cystamine / agmatine uses polyethylene glycol diacrylate as a support, and cystamine and agmatine are connected to the support.

[0011] Furthermore, the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel is a network-like high molecular weight polymer hydrogel formed by highly cross-linking the polymers.

[0012] Furthermore, the polyethylene glycol diacrylate is cross-linked with the primary amino groups of cystamine and agmatine through acrylate bonds.

[0013] Furthermore, as the polymer content in the polyethylene glycol diacrylate / cystamine / agmatine hydrogel increases, the surface structure of the gel becomes rougher.

[0014] Furthermore, the molecular formula of the polymer is:

[0015]

[0016] According to a second aspect of the present invention, a method for preparing the above-mentioned polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel is provided, wherein the preparation method comprises adding polyethylene glycol diacrylate, cystamine, and agmatine to deionized water with a pH value of 8.0-8.5 to carry out a Michael addition reaction.

[0017] Furthermore, in the above preparation method, the amount of ethylene glycol diacrylate added to 1 mL of deionized water is 0.65-1.35 mmol, the amount of cystamine added is 0.13-0.27 mmol, and preferably, the amount of agmatine added is 0.13-0.27 mmol.

[0018] Furthermore, the preparation method further comprises: determining the molar ratio of polyethylene glycol diacrylate to cystamine according to a predetermined gelation time of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel.

[0019] Furthermore, in the above preparation method, when the molar ratio of polyethylene glycol diacrylate, cystamine and agmatine is 1.35:0.27:0.27, a stable polyethylene glycol diacrylate / cystamine / agmatine hydrogel can be formed at 80° C. within 24 hours.

[0020] Furthermore, in the above preparation method, by changing the temperature of the Michael addition reaction, the degradation rate of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel also changes accordingly.

[0021] According to a third aspect of the present invention, there is provided the use of the above-mentioned polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel or the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel prepared by the above-mentioned preparation method in the preparation of biomaterials for repairing and restoring the function of nerve damage sites.

[0022] Furthermore, as the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel degrades, agmatine is continuously released.

[0023] Furthermore, the biomaterial can be delivered by injection.

[0024] The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel provided by the embodiments of the present invention and its preparation method and application have at least one or part of the following advantages:

[0025] (1) The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel (PCA medical hydrogel) of the embodiment of the present invention is obtained by cross-linking a polymer composed of polyethylene glycol diacrylate, cystamine, and agmatine connected by Michael addition reaction. The polymers are highly cross-linked, and the hydrogel surface has no porous structure. It has good adhesion, hydrophilicity and biocompatibility, and has good mechanical properties. The Young's modulus is 10.24KPa-26.02KPa and the maximum compressive strength is below 2N. It is used in the treatment of brain injuries and can provide suitable scaffold support for the cavity formed at the injury site, promote the regeneration of cells at the injury site, and enhance the recovery of brain function and structure.

[0026] (2) The PCA medical hydrogel provided in the embodiments of the present invention can reduce the level of ROS at the injured site and promote the regeneration and repair of damaged brain tissue. It can significantly reduce the activity of nitric oxide synthase in macrophages and reduce the concentration of NO in the body, thereby reducing the secretion of harmful substances at the damaged site in the early stage of central nervous system injury. The PCA medical hydrogel provided in the embodiments of the present invention was applied to a traumatic brain injury model. Through behavioral evaluation, it was demonstrated that the PCA medical hydrogel can effectively promote the recovery of movement, learning, and memory abilities in rats with brain injury. At the same time, it was verified that the PCA hydrogel has a significant effect on inhibiting the proliferation of adhesive marks and inflammatory reactions at the injured site of the rat brain.

[0027] (3) The degradation performance of the hydrogel provided by the embodiment of the present invention affects the efficiency of tissue regeneration at the implant site. If the hydrogel degrades too quickly, the newly grown tissue will lose its attachment and cannot be fully repaired; if the degradation is too slow, the growth of the newly grown tissue will be hindered. The introduction of disulfide bonds into the PCA medical hydrogel provided by the embodiment of the present invention can, on the one hand, enhance cell adhesion and facilitate the regeneration of cells at the site of loss; on the other hand, it makes the degradation of the PCA medical hydrogel reduction-sensitive. Under reducing conditions, the degradation rate will be accelerated, and the degradation of the hydrogel can be regulated by changes in the microenvironment.

[0028] (4) The PCA medical hydrogel provided in the embodiment of the present invention has shear thinning properties and is therefore injectable, which is beneficial for the delivery of the hydrogel via minimally invasive methods.

[0029] (5) The preparation method of the PCA medical hydrogel provided in the embodiment of the present invention is simple and controllable. The degradation rate of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel and the release rate of agmatine or cystamine can be controlled by changing the temperature of the Michael addition reaction, the dosage ratio of the three raw materials or the concentration of the reaction system. The swelling properties, hydrophilicity, mechanical properties, etc. of the PCA medical hydrogel can also be controlled by changing the concentration of the reaction system, so that the PCA medical hydrogel is more conducive to the repair and functional recovery of the nerve injury site, providing a promising biochemical material for in-depth research in the field of nerve regeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] These and / or other aspects and advantages of the present invention will become apparent and readily understood from the following description of the preferred embodiments taken in conjunction with the accompanying drawings, in which:

[0031] Figure 1 Schematic diagram of the synthesis of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel according to one embodiment of the present invention;

[0032] Figure 2 Scanning electron micrographs of the surface structures of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogels synthesized at three different molar ratios according to one embodiment of the present invention, wherein Figures a and d are PCA-1, Figures b and e are PCA-2; and Figures c and f are PCA-3.

[0033] Figure 3Figures 1 and 2 are mechanical property test graphs of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogels synthesized at 80°C according to one embodiment of the present invention, wherein Figure A is a test graph of the PCA-1 reaction monitored by rheological oscillatory shear; Figure B is a test graph of the PCA-2 reaction monitored by rheological oscillatory shear; Figure C is a test graph of the PCA-3 reaction monitored by rheological oscillatory shear; Figure D is a stress-strain curve graph of the three groups of hydrogels, PCA-1, PCA-2, and PCA-3; Figure E is a Young's modulus test graph of the three groups of hydrogels; and Figure F is a maximum load-bearing strength test graph of the three groups of hydrogels.

[0034] Figure 4 This is a test result diagram showing the effect of shear rate on the viscosity of three groups of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogels according to one embodiment of the present invention;

[0035] Figure 5 Figures 1 and 2 show the test results of the physical and chemical properties of three groups of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogels synthesized at 80° C. according to one embodiment of the present invention. Figure A shows the test results of the swelling rates of the three groups of hydrogels, Figure B shows the test results of the degradation rates of the three groups of hydrogels after treatment with PBS, and Figure C shows the test results of the degradation rates of the three groups of hydrogels after treatment with the reducing agent TCEP.

[0036] Figure 6 Schematic diagrams of the contact angles of three groups of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogels according to one embodiment of the present invention, wherein Figure A is a schematic diagram of the contact angles of the three groups of hydrogels, Figure B is a statistical result graph of the contact angles of the three groups of dry hydrogels, and Figure C is a statistical result graph of the contact angles of the three groups of wet hydrogels (****P<0.0001);

[0037] Figure 7 The test results of the effects of three groups of hydrogels on the viability of L929 cell lines after 1 day and 3 days of MTT assay according to Examples 1, 2 and 3 of the present invention are shown;

[0038] Figure 8 Figures 1 and 2 are graphs showing the results of hemolysis experiments on the hydrogels obtained according to Examples 1, 2, and 3 of the present invention, wherein Figure A shows the hemolysis of the hydrogels subjected to the hemolysis experiment, Figure B shows the hemolysis of blood cells (scale bar: 50 μm), and Figure C shows the test results of the hemolysis rate.

[0039] Figure 9Statistical graphs of NO detection of hydrogels obtained according to Examples 1, 2, and 3 of the present invention, wherein Control 1: cells were not stimulated with LPS; PCA-1: LPS and hydrogel were added and incubated simultaneously; PCA-2: LPS and hydrogel were added and incubated simultaneously; PCA-3: LPS and hydrogel were added and incubated simultaneously (**P<0.01, ***P<0.001, ****P<0.001, ###P<0.001);

[0040] Figure 10 Statistical graph of the DCFH probe-labeled ROS fluorescence intensity of macrophages using the hydrogels obtained according to Examples 1, 2, and 3 of the present invention (significant difference markers, LPS: *, PCA-2: *, PCA-3: *. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001);

[0041] Figure 11 Figures 1 and 2 are the results of the hydrogel motor ability assessment and improved nerve injury repair scores obtained according to Examples 1, 2, and 3 of the present invention, wherein Figure A is a statistical graph of the rotarod time on days 1, 3, 7, 14, 21, and 28 after surgery, n=4, and Figure B is a graph of the improved nerve injury repair score on days 1, 3, 7, 14, 21, and 28 after surgery, n=4 (*P<0.05) (TBI: traumatic brain injury treatment; PCA-1: injection of PCA-1 hydrogel after brain trauma; PCA-2: injection of PCA-2 hydrogel after brain trauma; PCA-3: injection of PCA-3 hydrogel after brain trauma);

[0042] Figure 12 Figures 1 and 2 are graphs showing the learning ability test results of the hydrogels obtained according to Examples 1, 2, and 3 of the present invention; Figure A shows heat maps of the learning trajectories of rats a, b, c, and d, and heat maps of the spatial memory trajectories of rats after the platform is removed e, f, h, and g; Figure B shows the test results of the escape latency; Figure C shows the dwell time in the quadrant where the platform is located; and Figure D shows the crossing frequency (*P<0.05, **P<0.01, ***P<0.001, ****P<0.001, significant difference markers, LPS: *, PCA-2: #) (TBI: traumatic brain injury; PCA-1: injection of PCA-1 hydrogel after traumatic brain injury; PCA-2: injection of PCA-2 hydrogel after traumatic brain injury; PCA-3: injection of PCA-3 hydrogel after traumatic brain injury).

[0043] Figure 13 This is a hematoxylin-eosin staining image of the heart, liver, spleen, lung, and kidney of a rat brain trauma model four weeks after surgery using the hydrogels obtained in Examples 1, 2, and 3 of the present invention;

[0044] Figure 14This is a coronal section of the brain of a rat treated with the hydrogels obtained in Examples 1, 2, and 3 of the present invention 4 weeks after traumatic brain injury;

[0045] Figure 15 This is a statistical diagram of positive cells in the coronal section of the brain of rats 4 weeks after traumatic brain injury after the hydrogels obtained in Examples 1, 2, and 3 of the present invention;

[0046] Figure 16 Coronal slice images and statistical graphs of the brain of rats treated with hydrogels obtained in Examples 1, 2, and 3 of the present invention 4 weeks after traumatic brain injury;

[0047] Figure 17 The diagram shows the statistical graph of positive cells in the coronal slices of the brain of rats 4 weeks after traumatic brain injury in the hydrogels obtained according to Examples 1, 2, and 3 of the present invention. DETAILED DESCRIPTION

[0048] The technical solution of the present invention will be further described in detail below through examples and in conjunction with the accompanying drawings. In the specification, the same or similar reference numerals indicate the same or similar components. The following description of the embodiments of the present invention with reference to the accompanying drawings is intended to explain the overall inventive concept of the present invention and should not be construed as limiting the present invention.

[0049] The reagents used in the examples are shown in the following table:

[0050]

[0051]

[0052] The preparation method of cystamine in the present invention is as follows: cystamine hydrochloride (2.25 g, 10 mmol) is dissolved in 30 mL of sodium hydroxide (0.8 g, 20 mmol) aqueous solution. The mixture is stirred under magnetic stirring for 1 hour, and the cystamine is extracted with dichloromethane. The mixture is dried over anhydrous sodium sulfate, and the organic solvent is evaporated to obtain cystamine.

[0053] The embodiment of the present invention provides a method for preparing PEGDA / CA / Agm medical hydrogel. The schematic diagram of the synthesis method is as follows: Figure 1 Specifically, polyethylene glycol diacrylate (PEGDA), cystamine (CA), and agmatine (Agm) are dissolved in deionized water (ddH2O) at a pH of 8.0-8.5 and heated to undergo a Michael addition reaction to obtain a PEGDA / CA / Agm medical hydrogel. The Michael addition reaction is performed at 25-80°C for 24-36 hours, preferably at 80°C for 24-36 hours.

[0054] In the embodiments of the present invention, the performance of the medical hydrogel can be controlled by adjusting the dosage ratio of polyethylene glycol diacrylate (PEGDA), cystamine (CA) and agmatine (Agm) or the concentration of the reaction system.

[0055] In some embodiments, the Young's modulus of the medical hydrogel can be regulated by changing the concentration of the reactants. Specifically, the Young's modulus of the medical hydrogel can be reduced by increasing the concentration of the reactants, or the Young's modulus of the medical hydrogel can be increased by decreasing the concentration of the reactants.

[0056] In some embodiments, the maximum compressive strength, swelling ratio, etc. of the medical hydrogel can be regulated by changing the concentration of the reactants. Specifically, by increasing the concentration of the reactants, the maximum compressive strength and swelling ratio of the medical hydrogel are increased.

[0057] In some embodiments, the hydrophilicity of the medical hydrogel can be controlled by changing the concentration of the reactants. Furthermore, by increasing the concentration of the reactants, the contact angle of the medical hydrogel is reduced, thereby enhancing the hydrophilicity of the medical hydrogel.

[0058] In some embodiments, the cross-linking degree of the medical hydrogel can be increased by increasing the concentration of reactants, thereby reducing the release rate of agmatine and cystamine, thereby achieving a slow release of agmatine and cystamine at the injury site.

[0059] Example 1

[0060] 0.65 mmol of polyethylene glycol diacrylate, 0.13 mmol of cystamine and 0.13 mmol of agmatine were added to 1 ml of ddH2O with a pH of 8.0 to obtain a mixed solution. The mixed solution was placed at 80°C for reaction for 24 hours to obtain polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel (PCA-1). The surface structure scanning electron microscope image is shown in FIG. Figure 2 As shown in Figures a and d.

[0061] It should be noted that in Example 1, only 1 ml of deionized water was used to prepare the medical hydrogel. Those skilled in the art can choose any volume of deionized water. For simplicity, the following examples are also described in a similar manner and will not be repeated here.

[0062] Example 2

[0063] 1.0 mmol of polyethylene glycol diacrylate, 0.2 mmol of cystamine and 0.2 mmol of agmatine were added to 1 ml of ddH2O with a pH of 8.3 to obtain a mixed solution. The mixed solution was placed at 80°C for reaction for 24 hours to obtain polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel (PCA-2). The surface structure scanning electron microscope image is shown in FIG. Figure 2 As shown in Figures b and e.

[0064] Example 3

[0065] 1.35 mmol of polyethylene glycol diacrylate, 0.27 mmol of cystamine and 0.27 mmol of agmatine were added to 1 ml of ddH2O with a pH of 8.5 to obtain a mixed solution. The mixed solution was placed at 80°C for reaction for 24 hours to obtain polyethylene glycol diacrylate / cystamine / agmatine hydrogel (PCA-3). The surface structure scanning electron microscopy image is shown in FIG. Figure 2 As shown in Figures c and f.

[0066] pass Figure 2 Scanning electron microscopy images of the surface structures of the three medical hydrogels show that as the concentration of the reaction system increases, the surface structure of the medical hydrogel becomes rougher. The rougher the surface structure of the medical hydrogel, the more favorable it is for cell adhesion and growth.

[0067] Comparative Example

[0068] 1.35 mmol of polyethylene glycol diacrylate, 0.27 mmol of cystamine, and 0.27 mmol of agmatine were added to 1 ml of ddH2O (pH 8.5) to form a mixed solution. The solution was reacted at 25°C for 3 hours to obtain a polyethylene glycol diacrylate / cystamine / agmatine hydrogel (PCA-4). This hydrogel self-degraded after being left at room temperature for 30 hours.

[0069] At 25°C, the presence of water as the reaction medium activates the amino groups and acrylates through hydrogen bonding, promoting the Michael addition reaction at room temperature. However, at room temperature, polyethylene glycol diacrylate and cystamine form shorter, more branched poly-beta-amino esters, resulting in a faster degradation rate for the hydrogel. This suggests that varying the temperature of the Michael addition reaction alters the degradation rate of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel.

[0070] Test Example 1: Compression Mechanics Test

[0071] The stress-strain curve, Young's modulus and maximum compressive strength of PCA medical hydrogel were tested using a universal electronic mechanical tensile machine. Figure 3 shown.

[0072] like Figure 3 As shown in the AC graph, the gelation times required for PCA-1, PCA-2, and PCA-3 are 2966±25.16s, 4397±42.06s, and 8421±59.97s, respectively. Increasing reactant concentration increases the gelation time, and the modulus of the gelled hydrogel decreases with increasing concentration.

[0073] like Figure 3 As shown in Figure 5D, the strain of the three medical hydrogels increases linearly with the increase of stress, among which PCA-1 has the smallest strain.

[0074] like Figure 3 As shown in E, the Young's modulus of the hydrogel in the PCA-1 group is the largest. As the concentration of the reactants increases, the Young's modulus of the medical hydrogel gradually decreases (PCA-1 = 26.02 ± 4.02 KPa, PCA-2 = 16.73 ± 4.1 KPa, PCA-3 = 10.24 ± 2.74 KPa). Figure 3 As shown in Figure 5, the maximum compressive strength of the medical hydrogel also shows a trend of increasing with increasing concentration. However, their average maximum compressive strength is below 2N, indicating that the colloid in the mechanical test is very soft.

[0075] Figure 4 The figure shows the test results of the effect of shear rate on the viscosity of polyethylene glycol diacrylate / cystamine / agmatine hydrogel. Figure 4 It can be seen that the test viscosity decreases with gradually increasing shear rate, indicating that PCA hydrogel has shear thinning function and can be loaded into a syringe to deliver materials by injection, thereby reducing secondary damage to the wound.

[0076] Test Example 2: Degradation Experiment

[0077] In PBS (pH = 7.4) buffer solution, the swelling and in vitro degradation experiments of polyethylene glycol diacrylate / cystamine / agmatine PCA hydrogel were carried out. Figure 5 As shown. Figure 5 As shown in A, as the concentration of polyethylene glycol diacrylate in the reactants increases, the swelling rate increases, indicating that the ability of the medical hydrogel to absorb liquid from the surrounding environment gradually increases.

[0078] like Figure 5 As shown in Figure B, PCA hydrogels exhibited a slow degradation trend in PBS solution. After 28 days of degradation, the degradation rates of PCA-1, PCA-2, and PCA-3 were 34.21±2.19%, 38.60±1.75%, and 41.49±4.55%, respectively. Due to the presence of cystamine in the hydrogels, they are reduction-sensitive. Therefore, the reducing agent TCEP (tris(2-carboxyethyl)phosphine hydrochloride) was used for degradation experiments.

[0079] like Figure 5As shown in Figure C, after 28 days of degradation in a 20 mmol / L TCEP solution, the degradation rates of PCA-1, PCA-2, and PCA-3 were 45.28±1.56%, 69.52±6.24%, and 74.09±2.07%, respectively. This indicates that the medical hydrogel can accelerate the degradation of the hydrogel under reducing conditions.

[0080] Test Example 3: Hydrophilicity Test

[0081] like Figure 6 As shown in Figure A, the contact angles of the hydrogels under wet and dry conditions were tested by a contact angle meter.

[0082] like Figure 6 As shown in Figure B, under dry conditions, the contact angles of the three medical hydrogels PCA-1, PCA-2 and PCA-3 were 42.45±1.29°, 36.46±1.74° and 25.63±1.30°, respectively.

[0083] like Figure 6 As shown in Figure C, the contact angles of the three medical hydrogels decreased significantly under wet conditions. The contact angles of polyethylene glycol diacrylate / cystamine / agmatine hydrogels PCA-1, PCA-2, and PCA-3 were 20.33±1.46°, 13.38±1.12°, and 10.25±0.74°, respectively.

[0084] The above experimental results show that as the concentration of medical hydrogel increases, the contact angle gradually decreases and the hydrophilicity gradually becomes stronger.

[0085] Test Example 4: Cytotoxicity Assay

[0086] 1 mL of the swollen equilibrium PCA medical hydrogel (PCA-1, PCA-2, PCA-3) was taken and immersed in 10 mL of complete culture medium for 24 h to prepare the hydrogel extract.

[0087] L929 fibroblasts were seeded at 5×10 3 / well in a 96-well plate (n=6), and 200 μL of hydrogel extract was added to each well. After culturing for 1 day and 3 days, 10 μL of MTT solution was added to each well, and the cells were placed in an incubator in the dark and incubated for 4 hours. Then, 100 μL of DMSO was added to each well, and the cells were placed in a shaker in the dark and shaken at 37°C for ≥4 hours to allow the formazan to fully dissolve.

[0088] like Figure 7 As shown, the absorbance of each well at 570 nm was detected by a microplate reader and the cell viability was calculated. After 1 day of culture, the cell viability was greater than 85%, and after 3 days of culture, the cell viability was greater than 100%, indicating that the prepared polyethylene glycol diacrylate / cystamine / agmatine PCA-1, PCA-2 and PCA-3 had no cytotoxicity.

[0089] Test Example 5: Hemolysis Detection

[0090] Collect 2 mL of rabbit blood using a blue-capped anticoagulant tube (BD, 9NC Coagulant sodium citrate 3.8%), take 1 mL of healthy fresh anticoagulated rabbit blood, and dilute it with 1.25 mL of 0.9% saline to prepare diluted anticoagulated rabbit blood. Place 5 mL of saline suspension containing the test sample (5 mg / mL) in a 15 mL centrifuge tube. Add 5 mL of distilled water to each tube of the positive control group and 5 mL of saline to each tube of the negative control group. Place all centrifuge tubes in a 37°C incubator and incubate for 30 minutes. After the incubation time is over, add 100 μL of preheated diluted anticoagulated rabbit blood to each tube and incubate in a 37°C incubator for 1 hour. Centrifuge at room temperature (3000 rpm, 5 minutes). Pipette 300 μL of supernatant into a 96-well plate, use a microplate reader to detect the absorbance value A at a wavelength of 545 nm, and calculate the hemolysis rate.

[0091] like Figure 8 As shown, the red blood cells in the poly(ethylene glycol diacrylate) / cystamine / agmatine) PCA-1, PCA-2, and PCA-3 groups were no different from those in the saline group. Distilled water (H2O) was used as a positive control, revealing that the red blood cells swelled and ruptured due to water absorption, lacking intact cell morphology. Using a microplate reader, the hemolysis rates of the hydrogels PCA-1, PCA-2, and PCA-3 were 0.198±0.12%, 0.115±0.12%, and 0.365±0.12%, respectively, all below 5%, demonstrating that the poly(ethylene glycol diacrylate) / cystamine / agmatine PCA-1, PCA-2, and PCA-3 hydrogels have good blood compatibility.

[0092] Test Example 6: Nitric Oxide Detection

[0093] The cells were digested with trypsin (0.25%) and the macrophage cell line (RAW.264.7) was cultured at a rate of 5×10 5 / well were seeded in 24-well plates. 500 μL of complete culture medium was added to the cells in the blank group, and an equal amount of complete culture medium containing LPS (100 μg / mL) was added to the cells in the control group. 0.01 g of swollen and balanced hydrogel and an equal amount of complete culture medium containing LPS were added to each well of the experimental group, and the cells were cultured in a cell culture incubator for 24 hours (4 parallel wells per group). The content of nitric oxide (NO) in the culture medium was detected using a nitric oxide detection kit. Griess Reagent I and II were taken out of the -20°C refrigerator and allowed to dissolve at room temperature. The standard was diluted with complete culture medium to a dilution concentration of 5, 10, 40, 60, and 100 μM / mL. The standard and sample were added to a 96-well plate at 50 μL / well.

[0094] like Figure 9 As shown, the NO concentration in the culture medium of normally cultured macrophages is 0.83±0.08 μmol / L. After lipopolysaccharide (LPS) stimulation of macrophages for 48 hours, the NO concentration in the culture medium is 4.17±0.20 μmol / L. When the macrophages are stimulated with LPS and the polyethylene glycol diacrylate / cystamine / agmatine PCA-1, PCA-2, and PCA-3 hydrogels are added simultaneously with LPS stimulation, the NO concentrations are 1.63±0.30 μmol / L, 2.56±0.36 μmol / L, and 2.92±0.28 μmol / L, respectively. This indicates that agmatine released from the medical hydrogel can significantly reduce nitric oxide synthase in macrophages. As the concentration of the medical hydrogel increases, the degree of cross-linking increases, resulting in a slower release of agmatine, allowing for a slow release of agmatine at the site of injury.

[0095] Test Example 7: Active Oxygen Detection

[0096] Place the treated small round glass slides (soaked overnight in 5% dilute hydrochloric acid, washed with water, cleaned with 95% ethanol, and dried) on the bottom of a 24-well plate. Use trypsin (0.25%) to digest the macrophage cell line (RAW264.7) and the cells are plated at 5×10 5 The cells were seeded at a density of 100 μg / well in a 24-well plate. 500 μL of complete culture medium was added to the cells in the negative control group, and an equal amount of complete culture medium containing LPS (100 μg / mL) was added to the cells in the positive control group. 0.01 g of swollen and balanced hydrogel and an equal amount of complete culture medium containing LPS were added to each well of the experimental group and cultured in a cell culture incubator for 48 h (4 parallel wells per group).

[0097] To detect reactive oxygen species using the fluorescent probe DCFH-DA, the probe was first loaded in situ. DCFH-DA was diluted with serum-free culture medium to a final concentration of 10 μmol / L. The cell culture medium was removed, and 200 μL of the diluted DCFH-DA solution was added to each well. The cells were incubated in a 37°C cell culture incubator for 20 minutes. The cells were washed three times with serum-free cell culture medium to fully remove the DCFH-DA that had not entered the cells. The fluorescence intensity before and after stimulation was measured using a laser confocal microscope, using an excitation wavelength of 488 nm and an emission wavelength of 525 nm.

[0098] like Figure 10As shown, 2',7'-dichlorofluorescein diacetate (DCFH) probes were used to label intracellular reactive oxygen species (ROS). The DCFH probe intensity was highest in the LPS group, while that in the polyethylene glycol diacrylate / cystamine / agmatine PCA-1, PCA-2, and PCA-3 hydrogels was lower than that in the LPS group, indicating that the medical hydrogels can reduce ROS levels. As the concentration of the medical hydrogel decreases, the DCFH probe intensity also decreases. As the concentration of the medical hydrogel increases, the degree of cross-linking increases, resulting in a slower release rate of cystamine, enabling a slower release of cystamine at the site of injury. Cystamine released from the medical hydrogel can be broken down into sulfinic acid by intracellular ROS, reducing ROS levels at the site of injury.

[0099] Test Case 8: Behavioral Assessment of Brain Injury Model

[0100] A traumatic brain injury model was constructed in SD rats. A 5mm diameter bone window was formed in the left parietal cortex of the rat brain at 3mm and 2mm outside the midline using a skull drill. A 60g impact hammer was dropped freely from a height of 20cm to a depth of 3mm to induce moderate traumatic brain injury. 0.5mL of the prepared hydrogel was injected into the surface of the injured area. The recovery of the mouse brain injury was evaluated by motor ability assessment, modified neurological severity score and learning ability test.

[0101] Figure 11 The results of the hydrogel motility assessment and improved nerve injury repair score obtained according to Examples 1, 2, and 3 of the present invention are shown in FIG. Figure 12 Graph showing the learning ability test results of the hydrogels obtained according to Examples 1, 2, and 3 of the present invention.

[0102] Brain injury in rats is usually accompanied by decreased motor ability. The rotarod fatigue test was used to evaluate the effect of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel on the motor ability of rats after brain injury. Before acute brain injury, the rats underwent rotarod fatigue training for three days.

[0103] like Figure 11 As shown in Figure A, a rotarod fatigue test was performed on rats after acute brain injury. The rotarod time statistics were recorded after the rats stayed on the rotarod fatigue instrument 1d, 3d, 7d, 14d, 21d, and 28d after surgery. It can be seen that during the postoperative observation period, the motor ability of the rats in the hydrogel injection group was stronger than that of the control TBI group. The motor ability of the polyethylene glycol diacrylate / cystamine / agmatine PCA-2 hydrogel was the strongest, followed by PCA-1 and PCA-3 hydrogels, and the control TBI group had the worst motor ability. This shows that the medical hydrogel group can effectively promote the repair of damaged brain tissue.

[0104] The modified Neurological Severity Score (mNSS) is a combination of motor, sensory, reflex, and balance tests used to assess the severity of trauma. Traumatic brain injury can severely affect neuromotor function, and the mNSS is used to assess the recovery of neuromotor function.

[0105] like Figure 11 As shown in Figure B, the modified nerve injury repair score (mNss) was performed 1d, 3d, 7d, 14d, 21d, and 28d after surgery, and the rats were scored through motor experiments, sensory experiments, balance beam experiments, reflex loss, and abnormal movement examinations. The lower the score, the better the recovery of the rat. It can be seen that twenty-eight days after surgery, the PCA-2 (1.0±0.0) and PCA-3 (1.0±0.5) hydrogel groups had the lowest modified nerve injury repair scores, followed by PCA-1 (1.38±0.41) hydrogel, and the TBI group had the highest score (2.0±1.0). The above results show that the hydrogel group can effectively promote the repair of damaged brain tissue.

[0106] The rats' learning ability was tested by water maze test. On the 22nd day after surgery, the rats were subjected to a 4-day water maze test.

[0107] like Figure 12 As shown in Figure A, Cured L earning is a heat map of the movement trajectory of rats in the water maze device on the 26th day after surgery. The quadrant where the small platform is located is the second quadrant (the upper right of the figure is the second quadrant area). The movement trajectory represents the rat's ability to learn and find the platform. The closer the trajectory is to the second quadrant and the more concentrated it is, the better the rat's learning ability. It can be clearly observed that the rats in the TBI group have been moving around the outer ring of the device, showing poor learning ability. Among them, the movement trajectory of the rats in the PCA-1 hydrogel injection treatment group is more concentrated, and they purposefully search for the small platform in the first and second quadrants, showing a strong learning ability. Comparing the movement trajectory diagrams of the rats treated with the three groups of hydrogels, the movement trajectory becomes more dispersed as the gel concentration increases.

[0108] like Figure 12 As shown in B, it shows the time it takes for rats to find the small platform in the water maze. On the first day of training, the time taken by TBI, PCA-1 hydrogel group, PCA-2 hydrogel group, and PCA-3 hydrogel group were 84.32±11.09s, 52.89±4.96s, 56.5±7.35s, and 70.38±9.42s, respectively. It can be seen that the rats treated with the hydrogel group learned faster. After four days of training, the time taken by the three groups of rats treated with PCA hydrogel to find the platform remained at around 6s, and the time taken by the rats in the TBI group (14.39±0.84s) was significantly higher than that of the hydrogel group. On the 26th day after the operation, the small platform in the device was removed, and the rats were allowed to move freely in the device for 2 minutes (the movement trajectory is shown in the figure). Figure 12 A).

[0109] like Figure 12 Figure C shows an analysis of the time rats spent in the second quadrant. Analysis of the time rats spent in the second quadrant showed that the PCA-2 hydrogel group (59.99 ± 3.81 s) spent the longest, followed by the PCA-3 hydrogel group (53.96 ± 2.10 s) and the PCA-1 hydrogel group (49.86 ± 3.28 s).

[0110] like Figure 12 Figure D shows the frequency of rats crossing the platform, with the tracking point set at the center of the rat's body (excluding the tail). The PCA-2 group (6.67±0.94) had the highest crossing frequency, followed by the PCA-3 group (5±0.82) and the PCA-1 group (3.67±0.47). The TBI group (1.67±0.47) had the fewest crossings. This indicates that the PCA-2 group was the most effective hydrogel in promoting learning and memory recovery in rats.

[0111] Test Example 9: Histological Detection

[0112] (1) H&E staining of visceral tissue

[0113] To further verify the systemic safety of polyethylene glycol diacrylate / cystamine / agmatine PCA hydrogel, hematoxylin-eosin staining was performed on the heart, liver, spleen, lung, and kidney of rats in the brain trauma model four weeks after surgery.

[0114] like Figure 13 As shown, no obvious structural damage, atrophy, fibrosis, or other pathological changes were observed in the PCA hydrogel, indicating that the PCA hydrogel did not cause tissue damage to the important organs of SD rats and was sufficiently safe for in vivo application.

[0115] (2) Immunofluorescence staining

[0116] like Figure 14 To further explore the repair mechanism, GFAP and MAP-2 antibodies were used to observe glial scar formation. Immunofluorescence staining of GFAP and MAP-2 was performed to determine the boundary between normal neural tissue and glial cells, observe the proliferation of fibrotic scars, and evaluate the inhibitory effect of PCA hydrogel on glial scar formation.

[0117] like Figure 15 As shown, semi-quantitative statistics of GPAF and MAP-2 positive cells were performed. The expression of GFAP in the cerebral cortex of rats in the TBI group was the highest, with significant differences. There was no significant difference in GFAP expression in the PCA hydrogel-treated group, and both groups inhibited the proliferation of glial scars.

[0118] (3) Immunofluorescence staining

[0119] like Figure 16 As shown, to analyze the anti-inflammatory effect of PCA hydrogel, IBA-1 in macrophages and activated microglia was detected by immunofluorescence analysis 28 days after injury by labeling with CD86 and IBA-1 antibodies.

[0120] like Figure 17 As shown in the figure, to assess the activation levels of macrophages and microglia, semi-quantitative analysis of CD86 and IBA-1 around the lesioned cortex was performed. The expression of macrophages (CD86) in the cerebral cortex tissue of the PCA-1 group was not significantly different from that of the TBI group, while PCA-2 and PCA-3 showed differences from the TBI group, with a decrease in macrophage number. The number of microglia (IBA1)-positive cells was statistically significant only in the PCA-2 hydrogel-treated group and the TBI group, while PCA-1 and PCA-3 showed no difference in expression between the two groups.

[0121] The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel provided by the embodiments of the present invention and its preparation method and application have at least one or part of the following advantages:

[0122] (1) The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel (PCA medical hydrogel) of the embodiment of the present invention is obtained by cross-linking a polymer composed of polyethylene glycol diacrylate, cystamine, and agmatine connected by Michael addition reaction. The polymers are highly cross-linked, and the hydrogel surface has no porous structure. It has good adhesion, hydrophilicity and biocompatibility, and has good mechanical properties. The Young's modulus is 10.24KPa-26.02KPa and the maximum compressive strength is below 2N. It is used in the treatment of brain injuries and can provide suitable scaffold support for the cavity formed at the injury site, promote the regeneration of cells at the injury site, and enhance the recovery of brain function and structure.

[0123] (2) The PCA medical hydrogel provided in the embodiments of the present invention can reduce the level of ROS at the injured site and promote the regeneration and repair of damaged brain tissue. It can significantly reduce the activity of nitric oxide synthase in macrophages and reduce the concentration of NO in the body, thereby reducing the secretion of harmful substances at the damaged site in the early stage of central nervous system injury. The PCA medical hydrogel provided in the embodiments of the present invention was applied to a traumatic brain injury model. Through behavioral evaluation, it was demonstrated that the PCA medical hydrogel can effectively promote the recovery of movement, learning, and memory abilities in rats with brain injury. At the same time, it was verified that the PCA hydrogel has a significant effect on inhibiting the proliferation of adhesive marks and inflammatory reactions at the injured site of the rat brain.

[0124] (3) The degradation performance of the hydrogel provided by the embodiment of the present invention affects the efficiency of tissue regeneration at the implant site. If the hydrogel degrades too quickly, the newly grown tissue will lose its attachment and cannot be fully repaired; if the degradation is too slow, the growth of the newly grown tissue will be hindered. The introduction of disulfide bonds into the PCA medical hydrogel provided by the embodiment of the present invention can, on the one hand, enhance cell adhesion and facilitate the regeneration of cells at the site of loss; on the other hand, it makes the degradation of the PCA medical hydrogel reduction-sensitive. Under reducing conditions, the degradation rate will be accelerated, and the degradation of the hydrogel can be regulated by changes in the microenvironment.

[0125] (4) The PCA medical hydrogel provided in the embodiment of the present invention has shear thinning properties and is therefore injectable, which is beneficial for the delivery of the hydrogel via minimally invasive methods.

[0126] (5) The preparation method of the PCA medical hydrogel provided in the embodiment of the present invention is simple and controllable. The degradation rate of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel and the release rate of agmatine or cystamine can be controlled by changing the temperature of the Michael addition reaction, the dosage ratio of the three raw materials or the concentration of the reaction system. The swelling properties, hydrophilicity, mechanical properties, etc. of the PCA medical hydrogel can also be controlled by changing the concentration of the reaction system, so that the PCA medical hydrogel is more conducive to the repair and functional recovery of the nerve injury site, providing a promising biochemical material for in-depth research in the field of nerve regeneration.

[0127] Although some embodiments of the present general inventive concept have been shown and described, it will be appreciated by those skilled in the art that changes may be made to these embodiments without departing from the principles and spirit of the present general inventive concept, the scope of which is defined in the claims and their equivalents.

Claims

1. A polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel, the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel comprising: Water molecules; The polymer of polyethylene glycol diacrylate / cystamine / agmatine uses polyethylene glycol diacrylate as a support, and cystamine and agmatine are connected to the support.

2. The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel according to claim 1, characterized in that: The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel is a network-like high molecular polymer hydrogel formed by highly cross-linking the polymers.

3. The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel according to claim 1, characterized in that: The polyethylene glycol diacrylate is cross-linked with the primary amino groups of cystamine and agmatine through an acrylate bond.

4. The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel according to claim 2, characterized in that: As the content of polymer in the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel increases, the surface structure of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel becomes rougher.

5. The polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel according to any one of claims 1 to 4, characterized in that: The molecular formula of the polymer is:

6. A method for preparing the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel as claimed in any one of claims 1 to 5, the preparation method comprising: Polyethylene glycol diacrylate, cystamine and agmatine are added into deionized water with a pH value of 8.0-8.5 to carry out Michael addition reaction, thereby obtaining the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel.

7. The preparation method according to claim 6, characterized in that: In 1 mL of deionized water, the amount of ethylene glycol diacrylate added is 0.65-1.35 mmol; the amount of cystamine added is 0.13-0.27 mmol.

8. The preparation method according to claim 7, characterized in that: The amount of agmatine substance added was 0.13-0.27 mmol.

9. The preparation method according to claim 8, characterized in that: When the molar ratio of polyethylene glycol diacrylate, cystamine and agmatine is 1.35:0.27:0.27, a stable polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel can be formed within 24 hours at 80°C.

10. The preparation method according to claim 8, characterized in that: By changing the temperature of the Michael addition reaction, the degradation rate of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel also changes accordingly.

11. Use of the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel as claimed in any one of claims 1 to 5 or the polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel prepared by the preparation method as claimed in any one of claims 6 to 10 in preparing biomaterials for repairing and restoring the function of nerve injury sites.

12. The use according to claim 11, characterized in that: Along with the degradation of polyethylene glycol diacrylate / cystamine / agmatine medical hydrogel, agmatine and cystamine are continuously released.

13. The use according to claim 12, characterized in that: The repair and function recovery biomaterial can be delivered by injection.